COPENHAGEN, Denmark —In this Healio video, Balazs Halmos, MD, MS, discusses results from the TOP trial, presented at European Lung Cancer Congress.
The phase 3 trial compared osimertinib (Tagrisso, AstraZeneca) plus chemotherapy with osimertinib alone in 294 patients with previously untreated nonsquamous non-small cell lung cancer with concurrent EGFR and TP53 mutations.
“Chemotherapy adds substantial value to osimertinib in terms of basically doubling the progression free survival,” Halmos, director of thoracic oncology and clinical cancer genomics at Montefiore Einstein Cancer Center, said.
Sources/Disclosures
Source:
Healio Interviews
Reference:
- Yang Y, et al. Abstract 2O. Presented at: European Lung Cancer Congress; March 25-28, 2026; Copenhagen, Denmark.
Disclosures:
Halmos reports research grants to institution from AbbVie, Amgen, Arrient, AstraZeneca, Black Diamond Therapeutics, , Boehringer Ingelheim, Daiichi, GSK, Janssen, Merck and Pfizer; consulting roles AstraZeneca, , Boehringer Ingelheim, Daiichi, EliLilly, Genentech, GSK, Johnson & Johnson, Merck, Pfizer and Takeda; and data and safety monitoring committee , eFECTOR and City of Hope and Nuvalent.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply